心脏缩:一个新的治疗目标?
Norbert Frey1, Hugo A Katus, Eric N Olson
1Department of Cardiology, University of Heidelberg (N.F., H.A.K.), Heidelberg, Germany.
Circulation
|April 7, 2004
概括
最近的研究质疑心脏缩是应对压力的必要性. 准分子通路可能允许抑制心脏缩而不会引起循环问题,提供了一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统上被视为补偿性的心脏缩,日益受到质疑.
- 最近对过度缩机制的分子洞察力正在出现.
- 由于抑制缩而导致循环不良的风险是一个关键问题.
研究的目的:
- 评估心脏缩的必要性作为对血液动力学压力的反应.
- 确定分子信号通路作为抑制缩的治疗点.
- 评估抗缩策略的潜在益处.
主要方法:
- 审查最近的研究质疑心脏缩的补偿作用.
- 对参与心脏缩的分子信号通路的分析.
- 来自动物模型和临床试验对抗高压干预措施的研究结果的摘要.
主要成果:
- 有证据表明,心脏缩可能并不总是必要或有益的.
- 特定的分子通路显示有望针对性治疗干预.
- 动物和临床数据表明抗缩策略的潜在益处.
结论:
- 抑制心脏缩可能在不损害循环功能的情况下实现.
- 准特定的分子通路为治疗心脏缩提供了一个有希望的途径.
- 抗高缩策略需要进一步的研究和开发.
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...


